Primary relevance to vitamin D Vitamin D is a stated subject of this paper.
Vitamin D is a stated subject of this paper; the supporting source evidence is shown below.
Why this paper is included
Supporting source evidence:
All Amgen studies were conducted in accordance with applicable country regulations and International Conference on Harmonisation (ICH) Good Clinical Practice (GCP) regulations/guidelines.Amgen-supported studies of cinacalcet in pediatric subjectsStudy ID(s), type, and objectivesDose regimenStudy populationClinical trials a20070208/NCT01277510 Double-blind, placebo-controlled Phase 3 RCT Primary objective To assess the safety and tolerability of cinacalcet including evaluation of AEs and incidence of hypocalcemia Other objectives To evaluate efficacy and bioanalytical parametersStarting dose: ≤ 0.2 mg/kg/day based on dry weightTitration: See Table 4Provision: Either as capsules for sprinkling or tabletsPlanned treatment duration:• Double-blind: 30 weeks• Open-label: 30 weeksN = 43 (n = 22 cinacalcet; n = 21 placebo)Key inclusion criteria• Aged 6 to < 18 years• Dry weight ≥ 12.5 kg at screening• PTH > 300 pg/mL• cCa ≥ 8.8 mg/dL• Receiving hemodialysis or peritoneal dialysis for ≥ 2 months before randomizationKey exclusion criteria• PTx within 6 months before or anticipated within 6 months after randomization• Treatment with cinacalcet within 1 month before randomization• A new onset of seizure or worsening of a preexisting seizure disorder within the last 3 months• Scheduled date for kidney transplant from a known living donor that makes completion of the study unlikely b20130356/NCT02138838 Open-label, active-controlled Phase 3 RCT Primary objective To assess the safety and tolerability of cinacalcet in pediatric subjects Other objectives To evaluate efficacy and bioanalytical parametersStarting dose: ≤ 0.2 mg/kg/day (based on dry weight)Titration: See Table 4.Provision: Either as capsules for sprinkling or tabletsPlanned treatment duration:• Open-label: 20 weeksN = 55 (n = 27* cinacalcet plus standard of care; n = 28 standard of care)*Only 25 of the enrolled patients received cinacalcetKey inclusion criteria• Aged 6 to < 18 years• PTH ≥ 300 pg/mL• cCa ≥ 8.8 mg/dL• Receiving hemodialysis or peritoneal dialysis for ≥ 30 days before screeningKey exclusion criteria• History of congenital long QT syndrome, second or third-degree heart block, ventricular tachyarrhythmias, or other conditions associated with prolonged QT interval• Corrected QT interval (QTc) > 500 ms, using Bazett’s formula• QTc ≥ 450 to ≤ 500 ms, using Bazett’s formula, unless written permission to enroll is provided by the investigator after consultation with a pediatric cardiologist a, b20110100/NCT01439867 Open-label, single-arm phase 2 study Primary objective To assess the safety and tolerability of cinacalcet in addition to standard of care in pediatric subjects age 28 days to < 6 years Other objectives Included PK, PD, and characterization of serum calciumStarting dose: 0.25a and 0.20b mg/kg/day based on dry weightTitration: 1 mg to 60 mgProvision: 5 mg capsules for sprinkling or mixed with sucrose syrup for oral administrationPlanned treatment duration:• 26 weeksN = 18Key inclusion criteria• Age 28 days to < 6 years at enrollmentc• Dry weight ≥ 7 kg at the time of screening• Screening plasma PTH level > 300 pg/mL (31.8 pmol/L) from the central laboratory, and not received any cinacalcet therapy for at least 30 days prior to start of dosing• Screening cCa from the central laboratory:○ ≥ 9.4 mg/dL (2.35 mmol/L) if age 28 days to < 2 years○ ≥ 8.8 mg/dL (2.2 mmol/L) if age ≥ 2 to < 6 years• Serum phosphorus from the central laboratory:○ ≥ 5.0 mg/dL (1.25 mmol/L) if age 28 days to < 1 year○ ≥ 4.5 mg/dL (1.13 mmol/L) if age ≥ 1 to < 6 years• sHPT not due to vitamin D deficiency, per investigator assessmentKey exclusion criteria• History of congenital long QT syndrome, second: or third-degree heart block, ventricular tachyarrhythmias or other conditions associated with prolonged QT interval• Corrected QT interval (QTc) > 500 ms, using Bazett’s formula• QTc ≥ 450 to ≤ 500 ms, using Bazett’s formula, unless written permission to enroll is provided by the investigator after consultation with a pediatric cardiologist b20140159/NCT02341417 Open-label, Phase 3 extension study: extension of 20130356 and 20110100 Primary objective To characterize the long-term safety and tolerability of cinacalcet in pediatric subjects with CKD receiving dialysis Other objectives To assess change in PTH, corrected serum calcium, and phosphateStarting dose: 0.2 mg/kg/day based on dry weightTitrations:• Subjects < 6 years old: 1, 2.5, 5, 7.5, 10, 15, 30, and 60 mg doses• Subjects ≥ 6 years old: 2.5, 5, 10, 15, 30, 60, 90, 120, and 180 mg dosesProvision: 5-mg capsules for sprinkling or 30-mg film-coated tablets for swallowingPlanned treatment duration:• 32 weeksN = 28 (27 enrolled from Study 20130356; 1 enrolled from Study 20110100); 13/27 subjects were on SOC in the parent study and subsequently treated with cinacalcet during the extension studyKey inclusion criteria• All subjects:○ Dialysate calcium concentration ≥ 2.5 mEq/L at day 1○ More than 14 days between the last study visit in Study 20130356 or Study 20110100 and screening for Study 20140159• All subjects from 20130356:○ Completed treatment through week 20 or on study at the time of Study 20130356 termination○ Dry weight ≥ 12.5 kg at day 1 of Study 20140159• Subjects randomized to the 20130356 Standard of Care Arm only:○ PTH ≥ 300 pg/mL (within 7 days of day 1)○ cCa ≥ 8.8 mg/dL (within 7 days of day 1)• All subjects from 20110100:○ Completed week 26 end of study visit or on study at the time of Study 20110100 termination○ Dry weight ≥ 7 kg at day 1 of Study 20140159Key exclusion criteria• Those listed above for Studies 20130356 and 20110100, plus:○ Unstable chronic heart failure during screening○ Received cinacalcet after the last study visit in Study 20130356 or Study 20110100 before day 1 of Study 20140159○ Scheduled date for kidney transplantation from a known living donor that makes completion of the study unlikely○ Either new or recurrent cardiac ventricular arrhythmias requiring a change in treatment within 10 days prior to screening visit or day 1 of Study 20140159 screening○ Hepatic impairment during screening 20090005/NCT01290029 Phase 1, open-label, single-dose study Primary objective To evaluate the safety and tolerability of a single-dose, oral administration of cinacalcet in pediatric subjects with CKD receiving dialysis Other objectives To evaluate the PK and PD of cinacalcet in pediatric subjects with CKD receiving dialysisStarting dose: 0.25 mg/kg (2 h fasting pre: and postadministration)Titration: n/aProvision: 5 mg capsulePlanned treatment duration:• Single doseN = 14Key inclusion criteria• Age 28 days to < 6 years• Body weight ≥ 6 kg at screening and at day − 1; gestational age 30 weeks; physical examination must be acceptable to investigator at screening and at day − 1• Serum calcium within age-appropriate normal ranges per NKF-K/DOQI guidelines at screening and at day − 1Key exclusion criteria• Current or historic malignancy• Cardiac ventricular arrhythmias within 28 days prior to screening• A gastrointestinal disorder or surgery• A new onset of seizure or worsening of a preexisting seizure disorder within 2 months prior to cinacalcet administration• Major surgery (involves general anesthesia or respiratory assistance) within 28 days prior to screening• History of prolongation of QT interval• Clinically significant abnormal electrocardiogram at screening and day 1 20030227 Phase 1, open-label, single-dose study.
Source: Methods. View original paper
Relevance classification does not establish study quality, causation or editorial approval.
Study design Study design awaiting verification.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.
Meta-analysis unclear · Open-label reported · Research setting awaiting verification
How this paper was classified
Automatic source-based classification; awaiting editorial verification. This is not a quality score.
The Amgen cinacalcet pediatric clinical development program consisted of two phase 3 randomized studies, one phase 3 single arm extension study, one open-label phase 2 study, and two open-label phase 1 studies.
Source: Methods.
What the study types mean
- Systematic review
- Uses explicit methods to identify, assess and summarise research on a defined question.
- Scoping review
- Maps the extent and characteristics of research on a topic.
- Narrative review
- Discusses existing research; systematic-review methods have not been established by this classification.
- Review / evidence synthesis
- Reviews existing research; the exact review methods need further assessment.
- Randomised controlled trial
- Assigns participants or groups to comparison interventions by chance.
- Non-randomised intervention study
- Examines an intervention without random allocation.
- Cohort study
- Examines exposures and outcomes over time within a defined group.
- Case-control study
- Compares people with an outcome against people without it, examining exposures.
- Cross-sectional study
- Examines a population at a particular point in time.
- Observational study
- Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
- Case report
- Describes an individual case.
- Case series
- Describes a group of individual cases.
- Secondary analysis
- Analyses existing study data; this paper is not automatically another independent trial.
- Laboratory study
- Investigates biological processes in a laboratory setting.
- Qualitative study
- Examines experiences or meanings using qualitative methods.
- Genetic instrumental-variable study
- Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
- Study protocol
- Describes planned methods and is not evidence that the planned study has reported results.
- Multiple reported designs
- More than one design is explicitly reported; examine the supporting methods.
- Study design awaiting verification
- The available source does not establish a sufficiently clear study design.
Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.
Abstracts
Cinacalcet studies in pediatric subjects with secondary hyperparathyroidism receiving dialysis
Study design awaiting verification · Pediatric Nephrology (Berlin, Germany) · 2020
Original publication title
Cinacalcet studies in pediatric subjects with secondary hyperparathyroidism receiving dialysis
© The Author(s) 2020
Original publication · Publisher record · CC BY 4.0
Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.
At a glance
Abstract: What background does the paper provide?
Secondary hyperparathyroidism (sHPT), a complication of chronic kidney disease (CKD) characterized by persistently elevated parathyroid hormone (PTH), alterations in calcium-phosphorus homeostasis, and vitamin D metabolism, affects 50% of children receiving dialysis. A significant proportion of these children develop CKD-mineral and bone disorder (CKD-MBD), associated with an increased risk of fractures and vascular calcification. The standard of care for sHPT in children includes vitamin D sterols, calcium supplementation, and phosphate binders. Several agents are approved for sHPT treatment in adults undergoing dialysis, including vitamin D analogs and calcimimetics, with limited information on their safety and efficacy in children.
The calcimimetic cinacalcet is approved for use in adults with sHPT on dialysis, but is not approved for pediatric use outside Europe.
Source: BackgroundAbstract: What methods does the paper describe?
This review provides dosing, safety, and efficacy information from Amgen-sponsored cinacalcet pediatric trials and data from non-Amgen sponsored clinical studies.
Source: MethodsAbstract: Electronic supplementary material
The online version of this article (10.1007/s00467-020-04516-4) contains supplementary material, which is available to authorized users.
Source: Electronic supplementary materialAbstract: Results
The Amgen cinacalcet pediatric clinical development program consisted of two Phase 3 randomized studies, one Phase 3 single arm extension study, one open-label Phase 2 study, and two open-label Phase 1 studies. Effects of cinacalcet on PTH varied across studies. Overall, 7.4 to 57.1% of subjects who received cinacalcet in an Amgen clinical trial attained PTH levels within recommended target ranges and 22.2 to 70.6% observed a ≥ 30% reduction in PTH. In addition, significant reductions in PTH were demonstrated in all non-Amgen-supported studies.
Source: ResultsAbstract: Conclusions
To help inform the pediatric nephrology community, this manuscript contains the most comprehensive review of cinacalcet usage in pediatric CKD patients to date.
Source: ConclusionsAuthors’ abstract
Background
Secondary hyperparathyroidism (sHPT), a complication of chronic kidney disease (CKD) characterized by persistently elevated parathyroid hormone (PTH), alterations in calcium-phosphorus homeostasis, and vitamin D metabolism, affects 50% of children receiving dialysis. A significant proportion of these children develop CKD-mineral and bone disorder (CKD-MBD), associated with an increased risk of fractures and vascular calcification. The standard of care for sHPT in children includes vitamin D sterols, calcium supplementation, and phosphate binders. Several agents are approved for sHPT treatment in adults undergoing dialysis, including vitamin D analogs and calcimimetics, with limited information on their safety and efficacy in children.
The calcimimetic cinacalcet is approved for use in adults with sHPT on dialysis, but is not approved for pediatric use outside Europe.
Methods
This review provides dosing, safety, and efficacy information from Amgen-sponsored cinacalcet pediatric trials and data from non-Amgen sponsored clinical studies.
Results
The Amgen cinacalcet pediatric clinical development program consisted of two Phase 3 randomized studies, one Phase 3 single arm extension study, one open-label Phase 2 study, and two open-label Phase 1 studies. Effects of cinacalcet on PTH varied across studies. Overall, 7.4 to 57.1% of subjects who received cinacalcet in an Amgen clinical trial attained PTH levels within recommended target ranges and 22.2 to 70.6% observed a ≥ 30% reduction in PTH. In addition, significant reductions in PTH were demonstrated in all non-Amgen-supported studies.
Conclusions
To help inform the pediatric nephrology community, this manuscript contains the most comprehensive review of cinacalcet usage in pediatric CKD patients to date.
Electronic supplementary material
The online version of this article (10.1007/s00467-020-04516-4) contains supplementary material, which is available to authorized users.
Publication and source details
Original title: Cinacalcet studies in pediatric subjects with secondary hyperparathyroidism receiving dialysis
Bradley A. Warady; Eric Ng; Laura Bloss; May Mo; Franz Schaefer; Justine Bacchetta
Pediatric Nephrology (Berlin, Germany) · 2020
© The Author(s) 2020https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.Amgen IncRepository JATS snapshot; version as supplied
Source retrieved: 2026-11-11T16:40:54.154594+00:00
DOI: 10.1007/s00467-020-04516-4 · PMC7385021